TY - JOUR AU - Tyzhnenko, Tetiana AU - Misiura, Kateryna AU - Kravchun, Nonna AU - Gorshunska, Maryana AU - Pochernyaev, Artem AU - Krasova, Nataliya AU - Gladkih, Alexander AU - Leshchenko, Zhanna AU - Fedorova, Ganna AU - Plohotnichenko, Olga AU - Hromakovska, Olena AU - Kolesnikova, Alla AU - Jansen, Eugene AU - Karachentsev, Yurii AU - Poltorak, Viktoriia PY - 2022/09/15 Y2 - 2024/03/29 TI - INVESTIGATION OF 2548G>A LEPTINE GENE POLYMORPHIC VARIANT IMPACT ON RISK OF NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS JF - Problems of Endocrine Pathology JA - PEP VL - 79 IS - 3 SE - DO - 10.21856/j-PEP.2022.3.06 UR - https://www.jpep.endocrinology.org.ua/index.php/1/article/view/1025 SP - 42-52 AB - <p><strong>Background. </strong>It is known that single nucleotide polymorphisms (SNPs) in adipokine genes can influence the development of pathological conditions associated with obesity, type 2 diabetes mellitus, non-alcoholic fatty liver disease and their complications. In this study, we aimed to investigate the link between common -2548G&gt;A (rs7799039) promoter variant of the human leptin gene (LEP) with leptin levels in type 2 diabetes patients with non-alcoholic fatty liver diseasese. <strong>Materials and methods. </strong>61 patients with T2D aged from 28 to 80 years old (34 men/27 women, age 56.40±0.62 yrs, diabetes duration 7.72±0.45 yrs, BMI 32.20±0.43 kg/m<sup>2</sup>, WHR 1,00 ±0,01, HbA<sub>1c </sub>7.80±0.19 %) with varying degrees of glycemic control and overweight, without renal insufficiency and 51 sex and age-match control subjects were examined. Genotyping according to SNP LEP 2548G&gt;A was performed using the polymerase chain reaction method with appropriate primers and HhaI endonuclease. <strong>Results</strong>. In our study of&nbsp; T2DM patients with NAFLD compared to T2DM patients without NAFLD features of dyslipidemia i.e. significant increase in triglycerides (p &lt;0,001), LDL cholesterol (p &lt;0,1), lower HDL cholesterol ( p &lt;0.001) were found. Stratification of the diabetic patients in the presence and absence of NAFLD showed&nbsp; more pronounced increase in circulating leptin levels in the presence of NAFLD (84.73 ± 13.80 vs. 52.57 ± 6.86 ng / ml, respectively), (p &lt;0.01), which justifies the feasibility of using this indicator for further needs as a diagnostic parameter of the above complication. In our study in GG carriers genotype of the G2548A LEP gene polymorphic locus type 2 diabetes patients with NAFLD the highest level of leptin was observed (159.15 ng/ml), compared to other genotypes. Thus, it can be assumed that the G allele is associated with increased leptin levels in the blood of patients with NAFLD. This study showed that women with type 2 diabetes mellitus carrying the GG genotype with the G-2458A polymorphic variant of the LEP gene have 3.4 times higher leptin levels than men carrying the same genotype (p&lt;0.03). The data obtained regarding the 2548G&gt;A polymorphic variant of the LEP gene can be used as a basis for personalized prevention and the formation of risk groups for the development of NAFLD.</p> ER -